Journal
MOVEMENT DISORDERS
Volume 21, Issue 2, Pages 136-141Publisher
WILEY
DOI: 10.1002/mds.20861
Keywords
GDNF; drug delivery; neuroimaging; clinical trials
Categories
Ask authors/readers for more resources
The development of a neuroprotective or neuroregenerative therapy for Parkinson's disease (PD) would be a major therapeutic advance. Unfortunately, results from a recent controlled clinical study delivering the neurotrophic factor, glial-derived neurotrophic factor (GDNF), directly into brain did not demonstrate efficacy and safety of such a treatment. A critical review of available data suggests that there are questions that need to be answered before the future of GDNF as a therapy for PD can be determined. (C) 2006 Movement Disorder Society.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available